구름버섯 (터키테일)

Macrophage-stimulating activity of polysaccharides extracted from fruiting bodies of Coriolus versicolor (Turkey Tail Mushroom).

1. J Med Food. 2006 Summer;9(2):175-81. doi: 10.1089/jmf.2006.9.175. Macrophage-stimulating activity of polysaccharides extracted from fruiting bodies of Coriolus versicolor (Turkey Tail Mushroom). Jeong SC(1), Yang BK, Kim GN, Jeong H, Wilson MA, Cho Y, Rao KS, Song CH. Author information: (1)D

Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer.

2. Cochrane Database Syst Rev. 2022 Nov 29;11(11):CD012053. doi: 10.1002/14651858.CD012053.pub2. Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Pilkington K(1), Wieland LS(2), Teng L(3), Jin XY(4), Storey D(5)

Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial.

1. Gut Microbes. 2014 Jul 1;5(4):458-67. doi: 10.4161/gmic.29558. Epub 2014 Jul 9. Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial. Pallav K(1), Dowd SE(2), Villafuerte J(1), Yang X(1), Kabbani T(1), Hansen J(1), Dennis M(1), Leffler DA(1), Newburg DS(3), Kelly CP(1). Author information: (1)The Celiac Center, Division of Gastroenterology; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston, MA USA. (2)Molecular Research LP; Shallowater, TX USA. (3)Program in Glycobiology; Boston College; Chestnut Hill, MA USA. BACKGROUND: Interactions between the microbial flora of the intestine and the human host play a critical role inmaintaining intestinal health and in the pathophysiology of a wide variety of disorders such as antibiotic associated diarrhea, Clostridium difficile infection, and inflammatory bowel disease. Prebiotics can confer health benefits by beneficial effects on the intestinal microbiome, whereas antibiotics can disrupt the microbiome leading to diarrhea andother side effects. AIM: To compare the effects of the prebiotic, polysaccharopeptide from Trametes versicolor, to those of the antibiotic,amoxicillin, on the human gut microbiome METHODS: Twenty-four healthy volunteers were randomized to receive PSP, amoxicillin, or no treatment (control).Stool specimens were analyzed using bTEFAP microbial ecology methods on seven occasions over 8 weeks from each participant in the active treatment groups and on three occasions for the controls. RESULTS: Twenty-two of 24 participants completed the protocol. PSP led to clear and consistent microbiome changes consistent with its activity as a prebiotic. Despite the diversity of the human microbiome we noted strong microbiome clustering among subjects. Baseline microbiomes tended to remain stable and to overshadow the treatment effects.Amoxicillin treatment caused substantial microbiome changes most notably an increase in Escherichia/Shigella. Antibiotic associated changes persisted to the end of the study, 42 days after antibiotic therapy ended. CONCLUSIONS: The microbiomes of healthy individuals show substantial diversity but remain stable over time.The antibiotic amoxicillin alters the microbiome and recovery from this disruption can take several weeks. PSP from T. versicolor acts as a prebiotic to modulate human intestinal microbiome composition. DOI: 10.4161/gmic.29558 PMID: 25006989 [Indexed for MEDLINE]

Insights into bioremediation of pharmaceuticals from wastewater streams: A meta-analysis of build type and organism selection.

2. J Environ Manage. 2025 Nov;394:127482. doi: 10.1016/j.jenvman.2025.127482. Epub 2025 Oct 3. Insights into bioremediation of pharmaceuticals from wastewater streams: A meta-analysis of build type and organism selection. Pantha K(1), Schultz N(1), Barton A(1), Long B(2). Author information: (1)Future Regions Research Centre, Federation University Australia, Ballarat, 3350, Victoria, Australia. (2)Future Regions Research Centre, Federation University Australia, Ballarat, 3350, Victoria, Australia. Electronic address: bm.long@federation.edu.au. Pharmaceuticals are widely used to manage health issues, but their release into the environment poses risks to human health and ecosystems, and most wastewater treatment plants are not designed to remove them. The suite of alternative treatments (e.g. ozonation, advanced oxidation) are expensive and intensive. Bioremediation techniques using plants, algae and fungi offer practical potential for pharmaceutical removal. This meta-analysis evaluates the effectiveness of plants, algae and fungi for removing pharmaceuticals from practical wastewater treatment systems-including constructed wetlands, hydroponics, batch and continuous reactors, and hybrid systems-with the aim of informing organism selection in such systems. Using the PRISMA guidelines, a database was compiled of findings from 203 published studies. This revealed that plant taxa such as Phragmites australis and Typha spp., fungi like Trametes versicolor, and algae like Chlorella spp., showed high removal efficiencies (>75 %) for multiple pharmaceuticals, particularly in constructed wetlands. Monocots generally showed higher mean removal efficiency than dicots. Continuous reactors, hybrid systems, and constructed wetlands emerged as the most effective bioremediation systems, particularly for removing antibiotics and analgesics. However, challenges persist in removing recalcitrant pharmaceuticals like antifungals, anxiolytics and antilipemics. The results underscore the potential of bioremediation technologies and identify research gaps in underexplored species that may enhance treatment effectiveness. By leveraging these findings, we can develop more effective and sustainable wastewater treatment solutions to mitigate the environmental and health risks associated with pharmaceutical pollution. Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.jenvman.2025.127482 PMID: 41045561 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Benjamin Long reports financial support was provided by Barwon Region Water Corporation, Central Highlands Water, Greater Western Water. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma.

3. Vet Comp Oncol. 2022 Sep;20(3):688-696. doi: 10.1111/vco.12823. Epub 2022 Apr 25. Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma. Gedney A(1), Salah P(1), Mahoney JA(1), Krick E(2), Martins R(1), Scavello H(1), Lenz JA(1), Atherton MJ(1)(3). Author information: (1)Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. (2)Mount Laurel Animal Hospital, Mount Laurel, New Jersey, USA. (3)Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Canine splenic hemangiosarcoma (HSA) is an aggressive tumour of vascular endothelium that carries a grave prognosis following standard of care treatment with surgery and doxorubicin. A previous pilot study revealed potential anti-tumour activity of I'm-Yunity polysaccharopeptide (PSP) for canine HSA. The aim of this prospective study was to assess patient outcome when treated with PSP alone or in combination with doxorubicin post-splenectomy compared to patients treated with surgery and doxorubicin that received a placebo in place of PSP. Dogs undergoing splenectomy for splenic HSA were eligible. Following splenectomy, owners were offered treatment with PSP alone or adjuvant doxorubicin chemotherapy (unblinded). Patients with owners that selected to proceed with doxorubicin chemotherapy were blindly randomized to receive placebo or PSP. Dogs were evaluated weekly for 15 weeks, then scheduled for monthly visits until death. One hundred and one dogs were included in the final analysis: 51 PSP alone, 25 doxorubicin/placebo, and 25 combination PSP/doxorubicin. On multivariate analysis, dogs treated with single agent PSP, female dogs, decreased haematocrit at diagnosis, and stage III disease were negatively significantly associated with outcome; however, an interaction between treatment group and sex was documented. Gender-specific outcomes revealed no significant difference in survival between treatment groups for male dogs, but female dogs treated with PSP alone had significantly reduced survival compared to females receiving doxorubicin/placebo (HR 0.21; p = .004). Anaemia (HR 5.28; p < .001) and stage III disease (HR 2.9; p = .014) remained negatively associated with survival when controlling for sex and treatment group. The addition of PSP to doxorubicin post-splenectomy did not improve survival in dogs with splenic HSA. © 2022 John Wiley & Sons Ltd. DOI: 10.1111/vco.12823 PMID: 35442554 [Indexed for MEDLINE]

Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study.

4. J Low Genit Tract Dis. 2021 Apr 1;25(2):130-136. doi: 10.1097/LGT.0000000000000596. Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study. Serrano L(1), López AC(2), González SP(1), Palacios S(3), Dexeus D(4), Centeno-Mediavilla C(5), Coronado P(6), de la Fuente J(7), López JA(8), Vanrell C(9), Cortés J(10). Author information: (1)HM Gabinete Velázquez, Madrid, Spain. (2)Hospital Quironsalud, Málaga, Spain. (3)Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain. (4)Women's Health Institute, Barcelona, Spain. (5)Clínica Diatros, Barcelona, Spain. (6)Hospital Clínico San Carlos, Madrid, Spain. (7)Hospital Universitario Infanta Leonor, Madrid, Spain. (8)Hospital General Universitario, Alicante, Spain. (9)Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. (10)Private Practice, Palma, Spain. Comment in J Low Genit Tract Dis. 2021 Oct 1;25(4):328. doi: 10.1097/LGT.0000000000000615. J Low Genit Tract Dis. 2021 Oct 1;25(4):329. doi: 10.1097/LGT.0000000000000616. OBJECTIVE: The aim of the study was to evaluate the efficacy of Papilocare, a Coriolus versicolor-based vaginal gel, in repairing human papillomavirus (HPV)-related low-grade cervical lesions. METHODS: The study is a multicenter, open-label, randomized, parallel-group, watchful waiting approach-controlled trial involving 91 HPV-positive women with low-grade Pap smear alterations and consistent colposcopy. RESULTS: The percentage of patients with normal Pap smear and concordant colposcopy 3 and 6 months after receiving treatment (78.0% and 84.9%) was significantly higher than without treatment (54.8% and 64.5%), especially in high-risk HPV patients (79.5% and 87.8% vs 52.0% and 56.0%). At 6-month visit, overall HPV clearance was achieved by a greater number of patients receiving treatment (59.6%) compared with those without treatment (41.9%), especially high-risk HPV ones (62.5% vs 40.0%). The cervical re-epithelization score was significantly higher with treatment (mean = 4.5) than without (mean = 4.1). Compared with baseline, perceived stress decreased in the treatment group (from 21.1 to 19.0) and increased in the control group (from 17.7 to 20.7). A total of 7 possible or probable treatment-related adverse events were reported, most of them (n = 6) being mild or moderate in severity. CONCLUSIONS: Treatment with Papilocare has demonstrated a better clinical benefit than the conventional watchful waiting approach in clinical practice for total and high-risk HPV patients in terms of its efficacy to treat HPV-related cervical lesions and to clear all HPV strains after a single 6-month period. It has demonstrated an adequate safety and tolerability and confers additional benefits such as higher re-epithelization, stress reduction, and high treatment adherence. Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP. DOI: 10.1097/LGT.0000000000000596 PMCID: PMC7984756 PMID: 33746195 [Indexed for MEDLINE] Conflict of interest statement: J.C. declares that he has received travel and/or research grants and/or honoraria for conferences and/or consultancy fees from Genómica, GSK, Merck, Procare Health, Qiagen, Roche, and SPMSD. S.P. declares that he has a financial relationship (as a scientific advisor, member of the advisory board, or consultant) with Pfizer, Amgen, MSD, Sandoz, Procare Health, Bayer, MSD, Serelys, and Shionogi. Furthermore, as a speaker or member of the advisory board, he has received research grants or honoraria from Servier, Pfizer, Abbott, Shionogi, Amgen, Novo Nordisk, Theramex, Bayer Healthcare, Serelys, and Gedeon Richter. D.D. declares that he has received speaking and consultancy fees from Sanofi Pasteur, MSD, and Procare Health. L.S. declares that he has received speaking and consultancy fees from Shionogi, Iprad, and Procare Health. A.C.L. declares that he has received consultancy fees from Procare Health. S.P.G. declares that she has received travel and/or research grants and/or honoraria for conferences and/or scientific advisory and consultancy fees from Isdín, Pfizer, Servier, Amgen, MSD, Kern-Gynea, Casen Recordati, Sandoz, Procare Health, Bayer, Lacer, Shionogi, GSK, Bioiberica, Theramex, Gedeon Richter, Iprad, Seid, Ordesa, and Zambon. C.V. declares that she has received speaking fees from Procare Health. C.C.-M. declares that she has received speaking fees from Bayer and a grant for congress attendance from GSK. P.C. declares that he has received travel grants, conference registration grants and/or honoraria for conferences, and/or consultancy fees from Genómica, GSK, MSD, Abex, Shionogi, Amgen, Lacer, and Pfizer. J.d.l.F. declares that he has received travel and/or research grants and/or honoraria for conferences and/or consultancy fees from GSK, Merck, Procare Health, Roche, SPMSD, Italfármaco, Adamed, Pfizer, and Effik. J.A.L. declares that he has received honoraria for lectures from Procare Health, Gedeon Richter, and Sanofi. The other authors have declared they have no conflicts of interest.

Control of oral human papillomavirus (HPV) by medicinal mushrooms, Trametes versicolor and Ganoderma lucidum: a preliminary clinical trial.

5. Int J Med Mushrooms. 2014;16(5):497-8. doi: 10.1615/intjmedmushrooms.v16.i5.80. Control of oral human papillomavirus (HPV) by medicinal mushrooms, Trametes versicolor and Ganoderma lucidum: a preliminary clinical trial. Donatini B(1). Author information: (1)Medicine Information Formation, 40 rue du Dr Roux, 51350 Cormontreuil, France. This preliminary randomized study investigated the efficacy of medicinal mushrooms, Trametes versicolor (TV), Ganoderma lucidum (GL), and Laetiporus sulphureus (LS), on the clearance of oral human papillomavirus (HPV, serotypes 16 and 18). Among 472 patients who underwent oral swabs for gingivitis, 61 patients were positive for HPV16 or HPV18. Twenty patients were included in group 1 (LS) and 41 patients were included in group 2 (TV+GL) for 2 months. Polymerase chain reaction (PCR) for HPV was performed at inclusion and after 2 months. In group 1, the clearance was equal to 5% after 2 months of treatment. In group 2, the clearance was equal to 88% (P<0.001). The detection of HPV16 or HPV18 could become relevant in routine since positivity is frequent and because a harmless and costless treatment may exist. The use of TV+GL for the clearance of oral HPV deserves further investigation. DOI: 10.1615/intjmedmushrooms.v16.i5.80 PMID: 25271984 [Indexed for MEDLINE]